Cantor Fitzgerald Has Lowered Expectations for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH) had its price target lowered by analysts at Cantor Fitzgerald to $3.00 in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective points to a potential upside of 231.13% from the company’s previous close.

A number of other equities research analysts have also weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Nyxoah in a research note on Wednesday, August 19th. Piper Sandler reissued an “overweight” rating and issued a $6.00 target price (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Robert W. Baird set a $2.31 target price on Nyxoah in a research note on Thursday, August 6th. Wall Street Zen lowered Nyxoah from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. Finally, Oppenheimer set a $4.00 price target on Nyxoah in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.55.

Nyxoah Trading Up 5.8%

Shares of NASDAQ NYXH traded up $0.05 during midday trading on Tuesday, reaching $0.91. The company had a trading volume of 214,010 shares, compared to its average volume of 205,618. Nyxoah has a one year low of $0.80 and a one year high of $5.92. The company has a quick ratio of 2.31, a current ratio of 2.38 and a debt-to-equity ratio of 0.44. The firm’s fifty day moving average price is $1.40 and its 200-day moving average price is $2.60. The stock has a market cap of $35.12 million, a PE ratio of -0.36 and a beta of 1.65.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. The company had revenue of $8.76 million during the quarter, compared to the consensus estimate of $8.64 million. On average, equities research analysts anticipate that Nyxoah will post -1.44 earnings per share for the current year.

Institutional Trading of Nyxoah

Several hedge funds and other institutional investors have recently made changes to their positions in NYXH. IFP Advisors Inc boosted its stake in Nyxoah by 35.6% during the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after purchasing an additional 31,061 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Nyxoah during the 2nd quarter valued at $169,000. Finally, Readystate Asset Management LP bought a new position in shares of Nyxoah during the 2nd quarter valued at $351,000.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.